ANO1 and breast cancer: In addition, pharmacological inhibition of CaCC activity of ANO1 reduced cell viability in HNSCC, esophageal squamous cell carcinoma (ESCC) and breast cancer cells via inhibition of epidermal growth factor receptor (EGFR) and calmodulin-dependent protein kinase II (CAMKII) signaling [16].